Authorized purpose: iSchemaView RAPID processes CT perfusion, CTA, and MR studies to visualize and analyze diffusion and perfusion, including tissue blood-volume maps, and supports physician selection of eligible acute-stroke patients with known intracranial ICA or proximal MCA occlusion for thrombectomy.
Clinical role
Diffusion and perfusion processing to support physician assessment and patient selection.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain, intracranial vasculature, and perfusion regions
Key limitation
Keep in mind: Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: iSchemaView RAPID processes CT perfusion, CTA, and MR studies to visualize and analyze diffusion and perfusion, including tissue blood-volume maps, and supports physician selection of eligible acute-stroke patients with known intracranial ICA or proximal MCA occlusion for thrombectomy.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain, intracranial vasculature, and perfusion regions Input: Supported CT perfusion, CTA, and MR diffusion or dynamic perfusion studies.
Who uses it?Intended users: Trained radiologists, neurologists, and other qualified physicians.
What does the software produce?Output: Diffusion views, perfusion maps, tissue blood-volume results, and review displays.
What is its most important limitation?Key limitation: Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
Clinical takeaway. Clinical role: iSchemaView RAPID processes CT perfusion, CTA, and MR studies to visualize and analyze diffusion and perfusion, including tissue blood-volume maps, and supports physician selection of eligible acute-stroke patients with known intracranial ICA or proximal MCA occlusion for thrombectomy.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports performance validation testing and software verification and validation testing, stating that the system provides accurate representation of key processing parameters and met all design requirements and specifications, and that system performance was validated through the use of phantoms; the added thrombectomy-selection claim is described as based on retrospective clinical data evaluation, with no study size or results given. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
iSchemaView RAPID processes CT perfusion, CTA, and MR studies to visualize and analyze diffusion and perfusion, including tissue blood-volume maps, and supports physician selection of eligible acute-stroke patients with known intracranial ICA or proximal MCA occlusion for thrombectomy.
Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
The exact FDA document reports performance validation testing and software verification and validation testing, stating that the system provides accurate representation of key processing parameters and met all design requirements and specifications, and that system performance was validated through the use of phantoms; the added thrombectomy-selection claim is described as based on retrospective clinical data evaluation, with no study size or results given. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Additionally, iSchemaView conducted extensive performance validation testing and software verification and validation testing of the RAPID system." … "This performance validation testing demonstrated that the RAPID system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports performance validation testing and software verification and validation testing, stating that the system provides accurate representation of key processing parameters and met all design requirements and specifications, and that system performance was validated through the use of phantoms; the added thrombectomy-selection claim is described as based on retrospective clinical data evaluation, with no study size or results given. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Additionally, iSchemaView conducted extensive performance validation testing and software verification and validation testing of the RAPID system." … "This performance validation testing demonstrated that the RAPID system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K182130 FDA evidence package for iSchemaView RAPID
DesignFDA 510(k) or PMA decision evidence and product verification described in the exact submission.
PopulationBrain, intracranial vasculature, and perfusion regions
Scopeexact submission
Tested versioniSchemaView RAPID configuration described in K182130
IndependenceSponsor or vendor study
K182130
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K182130 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT perfusion, CTA, and MR diffusion or dynamic perfusion studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes DICOM CT perfusion, CTA, and MR input for perfusion and diffusion processing.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes one or more RAPID Servers connected to a hospital LAN inside the hospital firewall, plus an iSchemaView Server; configurations are Standard RAPID installed on a customer's Linux-based server or Virtual RAPID accessed online. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "RAPID is a software-only device consisting of one or more RAPID Servers (dedicated or virtual and an iSchemaView Server). The RAPID Server is an image processing engine that connects to a hospital LAN, inside the Hospital Firewall." … "Standard RAPID, which is installed directly on a customer's Linux-based server and integrated with medical image processing software such as commercial PACS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes one or more RAPID Servers connected to a hospital LAN inside the hospital firewall, plus an iSchemaView Server; configurations are Standard RAPID installed on a customer's Linux-based server or Virtual RAPID accessed online. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "RAPID is a software-only device consisting of one or more RAPID Servers (dedicated or virtual and an iSchemaView Server). The RAPID Server is an image processing engine that connects to a hospital LAN, inside the Hospital Firewall." … "Standard RAPID, which is installed directly on a customer's Linux-based server and integrated with medical image processing software such as commercial PACS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA package describes DICOM CT perfusion, CTA, and MR input for perfusion and diffusion processing.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
Vendor-wide
Checked 2026-10-25
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
Only trained radiologists, neurologists, and other qualified physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K182130 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K182130 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Acute-stroke selection support is limited by the labeled occlusion, bolus, motion, hemorrhage, timing, and image-quality exclusions; physicians retain the treatment decision.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. acute-stroke CT and MR analysis software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
14Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain, cerebral vasculature, and perfusion regions
Authorized purpose: Rapid Platform v6.0 is image-processing software for trained professionals that views, processes, and analyzes DICOM images from CT and MRI. It supports functional and dynamic datasets including CT perfusion, CT angiography, diffusion-weighted MRI, and dynamic contrast-enhanced CT or MRI, with maps and measurements for tissue perfusion, diffusion, and blood volume. Rapid CT-Perfusion and Rapid MR-Perfusion may aid physicians in selecting acute stroke patients with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery for endovascular thrombectomy, subject to the labeled imaging criteria, clinical requirements, and exclusions.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial vessels represented in CT perfusion, CTA, and MRI; tissue perfusion, diffusion, and contrast dynamics
Authorized purpose: Rapid processes CT, CTP, CTA, diffusion MRI, and dynamic-contrast MRI for stroke viewing, perfusion, volumetry, mismatch, and large-vessel-density support for trained professionals.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.